2025 Q4 -tulosraportti
Vain PDF
93 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·8 t sittenCircVec - disruptive platform. A small notice in today's Biostock, link in another post: "But if the circVec advantage also applies to secretory proteins in vivo, which we expect, we open up a whole new field of possibilities in chronic disease. Examples include wet AMD, obesity, rheumatoid arthritis, and other inflammatory conditions. It goes without saying that this is an issue with great medical need, and thus enormous commercial opportunities for those who can deliver high and sustained protein expression at low and safe therapeutic doses." "... which we expect..." Among other things, Obesity 😊 They have probably had longer conversations and conducted thorough investigations before this agreement was entered into. This does not happen on impulse but on a rational basis.- ·9 t sittenWell, I find it a bit amusing. Wild ride up and down today on news that doesn't justify any of the movements. But today showed the potential. Give us August/September, then we'll probably celebrate together.
·9 t sittenPost copied from TekInvestor. Quote Erik Wiklund "We have already shown that circVec can increase the expression of intracellular proteins up to 50 times. This creates several opportunities within monogenic diseases, where we focus on heart, eye, and central nervous system tissues. But if the circVec advantage also applies to secreted proteins in vivo, which is what we expect, we open up a whole new area of opportunities within chronic diseases. Examples could be wet AMD, obesity, rheumatoid arthritis, and other inflammatory conditions – it goes without saying that these are major medical needs that represent massive commercial opportunities for anyone who can deliver high and sustained protein expression at low and safe therapeutic doses." Even Wiklund is on the obesity track now. 💰💰 Imagine if Circio could get the body to double the production of GLP1, amylins and/or GIP.
Very exciting that the spread on circvec can have such a large range. The price today is a joke, a little new poc data and it should take a jump.- ·9 t sittenCircio + Avenue Biosciences – Merck or Lilly? (Pure speculation) Today's collaboration with Avenue Biosciences made me think a little. What we know: - Circio enters a research collaboration with Avenue to combine circVec with Avenue's AI-based platform for optimizing signal peptides and protein secretion. - The goal is to increase production and secretion of therapeutic proteins in AAV-based gene therapy. - Circio thus continues the strategy of testing circVec together with various technology platforms and partners. What is interesting: Avenue brought in Jens H. Vogel, Ph.D. to the board on July 2. He is Senior Vice President and Head of the Global Biologics Operating Unit at Merck & Co. (MSD), where he leads biologics production and has broad experience with mRNA, biologics, and industrialization of new platform technologies. That does not mean that Merck is collaborating with Circio. But it means that a very central Merck leader gains insight into Avenue's strategic development and the technology they are building around protein secretion. Now that Avenue also collaborates with Circio, there will be an indirect link between circVec and an environment with heavy Big Pharma experience. At the same time, Eli Lilly is still an interesting candidate when looking at Circio's previously announced, unnamed Top-5 feasibility program within AAV and CNS. Lilly has invested heavily in RNA and gene therapy, and their previous collaboration with Sangamo on CNS delivery makes the technological connection interesting. My personal assessment: - Lilly still fits best if one only looks at the original AAV/CNS program. - Merck has become more interesting after the Avenue collaboration, but for now only indirectly through the board connection. All of this is, of course, speculation. Circio has never stated who the Top-5 partner is, and there is no public information directly linking either Merck or Lilly to the company's ongoing feasibility program.
·9 t sittenAvenue Biosciences agreement: A new piece in the circVec platform Today's research collaboration between Circio and Avenue Biosciences contains neither upfront payments nor immediate financial effect. Nevertheless, the agreement addresses one of the most underestimated challenges in modern gene therapy: How to effectively get therapeutic proteins out of the cell and where they are supposed to act. To understand the significance, one must distinguish between two different parts of the value chain. Delivery vs. biological effect Through 2026, Circio has entered into several collaborations that focus on the delivery of circRNA to the correct cells and tissues. Delivery partners (Acuitas, GenAssist, Tcelltech) → Gets RNA safely into the cell. Avenue Biosciences (Payload optimization) → Attempts to improve what happens after circVec is inside the cell and protein production has started. For many biological drugs, protein production alone is not enough. The protein must also be effectively released into the bloodstream or surrounding tissue to provide therapeutic effect. Signal peptides: The cell's postal address For a cell to export a protein, it must contain a signal peptide. This functions as a molecular address label that sends the protein into the cell's secretory system for export. circVec (gene recipe) ↓ Protein production ↓ Signal peptide ↓ Protein released into tissue/blood Many genetic constructs use standardized signal peptides that are not necessarily optimal. Avenue uses machine learning and large-scale screening to identify signal peptides that can improve both the processing and secretion of proteins produced by circVec. Why is this interesting? Circio's hypothesis is that circVec can provide more long-lasting and effective protein expression than traditional linear RNA formats. If Avenue can simultaneously improve protein secretion, a potential synergy arises: circVec increases and prolongs protein production. Avenue attempts to increase the proportion of protein that actually reaches the target tissue. The goal is not just more protein per cell, but more therapeutic effect per dose. According to Circio's management, even a doubling of both expression and secretion could be very valuable to reduce dose levels and production costs. More than rare diseases? Perhaps the most interesting thing in BioStock's interview with CEO Erik Digman Wiklund is which markets he points to. While Circio's internal programs focus on heart, eye, and CNS, secretory proteins can potentially open up much larger disease areas: Wet AMD Obesity (obesitas) Rheumatoid arthritis Other chronic inflammatory diseases These are markets that are significantly larger than the monogenic diseases traditionally associated with gene therapy. If the technology works as hoped, it can eventually enable the production of therapeutic antibodies directly in the patient's body over a longer period. The big picture That this strategy hits a broader industry movement is illustrated by Tempest Therapeutics recently announcing further investment in in vivo CAR-T based on mRNA and lipid nanoparticles. Tempest does not directly validate circVec. But it shows that more and more players are investing in technologies that program cells directly inside the patient's body. For Circio, this is primarily a confirmation that the market the company is targeting exists and is growing. No evidence yet It is important to emphasize that today's agreement does not document any biological or therapeutic advantage. Avenue will first identify candidates through screening. Then Circio will test these in vitro and in vivo. Before such data are available, the collaboration is primarily a scientific hypothesis that must be validated. At the same time, the recent capital raise of 65 million USD gives the company the opportunity to carry out several parallel development tracks without losing focus on its internal programs. Conclusion The Avenue agreement is about more than protein secretion alone. It shows how Circio attempts to build a platform that addresses several of the bottlenecks between the RNA molecule and the final therapeutic effect in the patient. If the combination of long-lasting circRNA expression and improved protein secretion can be documented in upcoming studies, it can extend the platform's relevance far beyond current focus areas. Until such data are available, the agreement should primarily be seen as a strategic investment in future opportunities, rather than a short-term share price driver.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
93 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sittenCircVec - disruptive platform. A small notice in today's Biostock, link in another post: "But if the circVec advantage also applies to secretory proteins in vivo, which we expect, we open up a whole new field of possibilities in chronic disease. Examples include wet AMD, obesity, rheumatoid arthritis, and other inflammatory conditions. It goes without saying that this is an issue with great medical need, and thus enormous commercial opportunities for those who can deliver high and sustained protein expression at low and safe therapeutic doses." "... which we expect..." Among other things, Obesity 😊 They have probably had longer conversations and conducted thorough investigations before this agreement was entered into. This does not happen on impulse but on a rational basis.
- ·9 t sittenWell, I find it a bit amusing. Wild ride up and down today on news that doesn't justify any of the movements. But today showed the potential. Give us August/September, then we'll probably celebrate together.
- ·9 t sittenPost copied from TekInvestor. Quote Erik Wiklund "We have already shown that circVec can increase the expression of intracellular proteins up to 50 times. This creates several opportunities within monogenic diseases, where we focus on heart, eye, and central nervous system tissues. But if the circVec advantage also applies to secreted proteins in vivo, which is what we expect, we open up a whole new area of opportunities within chronic diseases. Examples could be wet AMD, obesity, rheumatoid arthritis, and other inflammatory conditions – it goes without saying that these are major medical needs that represent massive commercial opportunities for anyone who can deliver high and sustained protein expression at low and safe therapeutic doses." Even Wiklund is on the obesity track now. 💰💰 Imagine if Circio could get the body to double the production of GLP1, amylins and/or GIP.Very exciting that the spread on circvec can have such a large range. The price today is a joke, a little new poc data and it should take a jump.
- ·9 t sittenCircio + Avenue Biosciences – Merck or Lilly? (Pure speculation) Today's collaboration with Avenue Biosciences made me think a little. What we know: - Circio enters a research collaboration with Avenue to combine circVec with Avenue's AI-based platform for optimizing signal peptides and protein secretion. - The goal is to increase production and secretion of therapeutic proteins in AAV-based gene therapy. - Circio thus continues the strategy of testing circVec together with various technology platforms and partners. What is interesting: Avenue brought in Jens H. Vogel, Ph.D. to the board on July 2. He is Senior Vice President and Head of the Global Biologics Operating Unit at Merck & Co. (MSD), where he leads biologics production and has broad experience with mRNA, biologics, and industrialization of new platform technologies. That does not mean that Merck is collaborating with Circio. But it means that a very central Merck leader gains insight into Avenue's strategic development and the technology they are building around protein secretion. Now that Avenue also collaborates with Circio, there will be an indirect link between circVec and an environment with heavy Big Pharma experience. At the same time, Eli Lilly is still an interesting candidate when looking at Circio's previously announced, unnamed Top-5 feasibility program within AAV and CNS. Lilly has invested heavily in RNA and gene therapy, and their previous collaboration with Sangamo on CNS delivery makes the technological connection interesting. My personal assessment: - Lilly still fits best if one only looks at the original AAV/CNS program. - Merck has become more interesting after the Avenue collaboration, but for now only indirectly through the board connection. All of this is, of course, speculation. Circio has never stated who the Top-5 partner is, and there is no public information directly linking either Merck or Lilly to the company's ongoing feasibility program.
- ·9 t sittenAvenue Biosciences agreement: A new piece in the circVec platform Today's research collaboration between Circio and Avenue Biosciences contains neither upfront payments nor immediate financial effect. Nevertheless, the agreement addresses one of the most underestimated challenges in modern gene therapy: How to effectively get therapeutic proteins out of the cell and where they are supposed to act. To understand the significance, one must distinguish between two different parts of the value chain. Delivery vs. biological effect Through 2026, Circio has entered into several collaborations that focus on the delivery of circRNA to the correct cells and tissues. Delivery partners (Acuitas, GenAssist, Tcelltech) → Gets RNA safely into the cell. Avenue Biosciences (Payload optimization) → Attempts to improve what happens after circVec is inside the cell and protein production has started. For many biological drugs, protein production alone is not enough. The protein must also be effectively released into the bloodstream or surrounding tissue to provide therapeutic effect. Signal peptides: The cell's postal address For a cell to export a protein, it must contain a signal peptide. This functions as a molecular address label that sends the protein into the cell's secretory system for export. circVec (gene recipe) ↓ Protein production ↓ Signal peptide ↓ Protein released into tissue/blood Many genetic constructs use standardized signal peptides that are not necessarily optimal. Avenue uses machine learning and large-scale screening to identify signal peptides that can improve both the processing and secretion of proteins produced by circVec. Why is this interesting? Circio's hypothesis is that circVec can provide more long-lasting and effective protein expression than traditional linear RNA formats. If Avenue can simultaneously improve protein secretion, a potential synergy arises: circVec increases and prolongs protein production. Avenue attempts to increase the proportion of protein that actually reaches the target tissue. The goal is not just more protein per cell, but more therapeutic effect per dose. According to Circio's management, even a doubling of both expression and secretion could be very valuable to reduce dose levels and production costs. More than rare diseases? Perhaps the most interesting thing in BioStock's interview with CEO Erik Digman Wiklund is which markets he points to. While Circio's internal programs focus on heart, eye, and CNS, secretory proteins can potentially open up much larger disease areas: Wet AMD Obesity (obesitas) Rheumatoid arthritis Other chronic inflammatory diseases These are markets that are significantly larger than the monogenic diseases traditionally associated with gene therapy. If the technology works as hoped, it can eventually enable the production of therapeutic antibodies directly in the patient's body over a longer period. The big picture That this strategy hits a broader industry movement is illustrated by Tempest Therapeutics recently announcing further investment in in vivo CAR-T based on mRNA and lipid nanoparticles. Tempest does not directly validate circVec. But it shows that more and more players are investing in technologies that program cells directly inside the patient's body. For Circio, this is primarily a confirmation that the market the company is targeting exists and is growing. No evidence yet It is important to emphasize that today's agreement does not document any biological or therapeutic advantage. Avenue will first identify candidates through screening. Then Circio will test these in vitro and in vivo. Before such data are available, the collaboration is primarily a scientific hypothesis that must be validated. At the same time, the recent capital raise of 65 million USD gives the company the opportunity to carry out several parallel development tracks without losing focus on its internal programs. Conclusion The Avenue agreement is about more than protein secretion alone. It shows how Circio attempts to build a platform that addresses several of the bottlenecks between the RNA molecule and the final therapeutic effect in the patient. If the combination of long-lasting circRNA expression and improved protein secretion can be documented in upcoming studies, it can extend the platform's relevance far beyond current focus areas. Until such data are available, the agreement should primarily be seen as a strategic investment in future opportunities, rather than a short-term share price driver.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
93 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sittenCircVec - disruptive platform. A small notice in today's Biostock, link in another post: "But if the circVec advantage also applies to secretory proteins in vivo, which we expect, we open up a whole new field of possibilities in chronic disease. Examples include wet AMD, obesity, rheumatoid arthritis, and other inflammatory conditions. It goes without saying that this is an issue with great medical need, and thus enormous commercial opportunities for those who can deliver high and sustained protein expression at low and safe therapeutic doses." "... which we expect..." Among other things, Obesity 😊 They have probably had longer conversations and conducted thorough investigations before this agreement was entered into. This does not happen on impulse but on a rational basis.
- ·9 t sittenWell, I find it a bit amusing. Wild ride up and down today on news that doesn't justify any of the movements. But today showed the potential. Give us August/September, then we'll probably celebrate together.
- ·9 t sittenPost copied from TekInvestor. Quote Erik Wiklund "We have already shown that circVec can increase the expression of intracellular proteins up to 50 times. This creates several opportunities within monogenic diseases, where we focus on heart, eye, and central nervous system tissues. But if the circVec advantage also applies to secreted proteins in vivo, which is what we expect, we open up a whole new area of opportunities within chronic diseases. Examples could be wet AMD, obesity, rheumatoid arthritis, and other inflammatory conditions – it goes without saying that these are major medical needs that represent massive commercial opportunities for anyone who can deliver high and sustained protein expression at low and safe therapeutic doses." Even Wiklund is on the obesity track now. 💰💰 Imagine if Circio could get the body to double the production of GLP1, amylins and/or GIP.Very exciting that the spread on circvec can have such a large range. The price today is a joke, a little new poc data and it should take a jump.
- ·9 t sittenCircio + Avenue Biosciences – Merck or Lilly? (Pure speculation) Today's collaboration with Avenue Biosciences made me think a little. What we know: - Circio enters a research collaboration with Avenue to combine circVec with Avenue's AI-based platform for optimizing signal peptides and protein secretion. - The goal is to increase production and secretion of therapeutic proteins in AAV-based gene therapy. - Circio thus continues the strategy of testing circVec together with various technology platforms and partners. What is interesting: Avenue brought in Jens H. Vogel, Ph.D. to the board on July 2. He is Senior Vice President and Head of the Global Biologics Operating Unit at Merck & Co. (MSD), where he leads biologics production and has broad experience with mRNA, biologics, and industrialization of new platform technologies. That does not mean that Merck is collaborating with Circio. But it means that a very central Merck leader gains insight into Avenue's strategic development and the technology they are building around protein secretion. Now that Avenue also collaborates with Circio, there will be an indirect link between circVec and an environment with heavy Big Pharma experience. At the same time, Eli Lilly is still an interesting candidate when looking at Circio's previously announced, unnamed Top-5 feasibility program within AAV and CNS. Lilly has invested heavily in RNA and gene therapy, and their previous collaboration with Sangamo on CNS delivery makes the technological connection interesting. My personal assessment: - Lilly still fits best if one only looks at the original AAV/CNS program. - Merck has become more interesting after the Avenue collaboration, but for now only indirectly through the board connection. All of this is, of course, speculation. Circio has never stated who the Top-5 partner is, and there is no public information directly linking either Merck or Lilly to the company's ongoing feasibility program.
- ·9 t sittenAvenue Biosciences agreement: A new piece in the circVec platform Today's research collaboration between Circio and Avenue Biosciences contains neither upfront payments nor immediate financial effect. Nevertheless, the agreement addresses one of the most underestimated challenges in modern gene therapy: How to effectively get therapeutic proteins out of the cell and where they are supposed to act. To understand the significance, one must distinguish between two different parts of the value chain. Delivery vs. biological effect Through 2026, Circio has entered into several collaborations that focus on the delivery of circRNA to the correct cells and tissues. Delivery partners (Acuitas, GenAssist, Tcelltech) → Gets RNA safely into the cell. Avenue Biosciences (Payload optimization) → Attempts to improve what happens after circVec is inside the cell and protein production has started. For many biological drugs, protein production alone is not enough. The protein must also be effectively released into the bloodstream or surrounding tissue to provide therapeutic effect. Signal peptides: The cell's postal address For a cell to export a protein, it must contain a signal peptide. This functions as a molecular address label that sends the protein into the cell's secretory system for export. circVec (gene recipe) ↓ Protein production ↓ Signal peptide ↓ Protein released into tissue/blood Many genetic constructs use standardized signal peptides that are not necessarily optimal. Avenue uses machine learning and large-scale screening to identify signal peptides that can improve both the processing and secretion of proteins produced by circVec. Why is this interesting? Circio's hypothesis is that circVec can provide more long-lasting and effective protein expression than traditional linear RNA formats. If Avenue can simultaneously improve protein secretion, a potential synergy arises: circVec increases and prolongs protein production. Avenue attempts to increase the proportion of protein that actually reaches the target tissue. The goal is not just more protein per cell, but more therapeutic effect per dose. According to Circio's management, even a doubling of both expression and secretion could be very valuable to reduce dose levels and production costs. More than rare diseases? Perhaps the most interesting thing in BioStock's interview with CEO Erik Digman Wiklund is which markets he points to. While Circio's internal programs focus on heart, eye, and CNS, secretory proteins can potentially open up much larger disease areas: Wet AMD Obesity (obesitas) Rheumatoid arthritis Other chronic inflammatory diseases These are markets that are significantly larger than the monogenic diseases traditionally associated with gene therapy. If the technology works as hoped, it can eventually enable the production of therapeutic antibodies directly in the patient's body over a longer period. The big picture That this strategy hits a broader industry movement is illustrated by Tempest Therapeutics recently announcing further investment in in vivo CAR-T based on mRNA and lipid nanoparticles. Tempest does not directly validate circVec. But it shows that more and more players are investing in technologies that program cells directly inside the patient's body. For Circio, this is primarily a confirmation that the market the company is targeting exists and is growing. No evidence yet It is important to emphasize that today's agreement does not document any biological or therapeutic advantage. Avenue will first identify candidates through screening. Then Circio will test these in vitro and in vivo. Before such data are available, the collaboration is primarily a scientific hypothesis that must be validated. At the same time, the recent capital raise of 65 million USD gives the company the opportunity to carry out several parallel development tracks without losing focus on its internal programs. Conclusion The Avenue agreement is about more than protein secretion alone. It shows how Circio attempts to build a platform that addresses several of the bottlenecks between the RNA molecule and the final therapeutic effect in the patient. If the combination of long-lasting circRNA expression and improved protein secretion can be documented in upcoming studies, it can extend the platform's relevance far beyond current focus areas. Until such data are available, the agreement should primarily be seen as a strategic investment in future opportunities, rather than a short-term share price driver.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt